{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:tafinlar:4 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Aema%3Atafinlar%3A4",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001688,
    "timestamp_received": "2026-11-09T16:13:58.552753Z",
    "timestamp_returned": "2026-11-09T16:13:58.554441Z",
    "trace_id": "0d31f58c-8cc7-488c-b1d3-278af6cb8014"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:ema:tafinlar:4",
      "type": "Indication",
      "description": "Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult and adolescents aged 12 years and older with Stage III melanoma with a BRAF V600 mutation, following complete resection.",
      "contributions": [
        {
          "id": "ctrb:ema:2026-04-30:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2026-04-30",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        },
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:tafinlar",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tafinlar (dabrafenib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised May 2026. Accessed August 2, 2026.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Novartis Europharm Limited.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tafinlar",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "dabrafenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2013-09-18",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2026-05-19",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult and adolescent patients aged 12 years and older with Stage III melanoma with a BRAF V600 variant, following complete resection.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}